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Abstract
Purpose Everolimus is a novel inhibitor of the mamma-
lian target of rapamycin pathway, which is aberrantly
activated in cancer cell. We conducted a phase I study of
capecitabine plus everolimus (RAD001) in refractory gas-
tric cancer patients.
Methods Patients with metastatic gastric cancer and
progression after prior chemotherapy were eligible. Four
dose levels were planned as follows: Level 1, 5 mg bid/day
of everolimus (D1-D21) and 500 mg/m
2 bid/day of cape-
citabine (D1-14); Level 2, 5 mg bid/day of everolimus
(D1-D21) and 750 mg/m
2 bid/day of capecitabine (D1-14);
Level 3, 5 mg bid/day of everolimus (D1-D21) and
1000 mg/m
2 bid/day of capecitabine (D1-14); and Level 4,
10 mg bid/day of everolimus (D1-D21) and 1000 mg/m
2
bid/day of capecitabine (D1-14). Treatment was repeated
every 3 weeks until disease progression, patient refusal, or
any serious adverse event.
Results Fifteen patients were enrolled in this study
between November 2009 and April 2010. Fifteen patients
were enrolled (median age, 50 years; men, 9). Six patients
had received two previous chemotherapy regimens; six
patients had three previous chemotherapy regimens before
the study treatment. Thus, the majority of patients were
heavily pretreated. The dose-limiting toxicities were grade
3 infection, grade 3 mucositis, and grade 3 hyperglycemia
and hyponatremia. After a median follow-up duration of
5.6 months (range, 2.3–8.1 months), median PFS was
1.8 months (95% CI, 0.8–2.8 months). The maximum best
change observed was a 28.7% decrease in sum of longest
diameters when compared with baseline.
Conclusions The combination of capecitabine and ever-
olimus showed satisfactory toxicity proﬁle and modest
clinical beneﬁt in patients with refractory gastric cancer.
The recommended dose of capecitabine and everolimus was
650 mg/m
2 twice daily and 5 mg twice daily, respectively.
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Introduction
Gastric cancer is the most common cancer type and the
major cause of cancer death in Korea [1]. The role of
cytotoxic chemotherapy has been extensively investigated
in metastatic gastric cancer in various settings. Despite this
rigorous endeavor, the response rate is still below 50% to
ﬁrst-line chemotherapy and the duration of response is as
short as a few months [2]. As was previously reported,
limited clinical trials have been conducted as salvage
treatment after failure to ﬁrst-line chemotherapy [3–5]. Our
retrospective analysis indicated that an overall response
rate was only 16% (95% CI, 13–19%) to second-line
chemotherapy and overall survival calculated from the date
of second-line chemotherapy was only 6.7 months (95%
CI, 5.8–7.5 months) [6]. Given the poor clinical outcome,
there is an urgent need for novel treatment in gastric cancer
patients, especially in salvage setting.
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DOI 10.1007/s00280-011-1653-5One of the promising candidates for novel targeted agent
is everolimus, an oral inhibitor of the mammalian target of
rapamycin (mTOR). Recently, phase II study of everolimus
monotherapy demonstrated promising disease control rate
of 56.0% (95% CI, 41.3–70.0%) in second- or third-line
setting [7]. mTOR, a serine/threonine kinase, is involved in
the control of translation in response to insulin and various
endogenous growth factors via the PI3 K/Akt pathway and
cellular nutrient and is thought to play a central role in
regulating cell growth, cell cycle progression, and tumor-
igenesis [8, 9]. Previous studies including ours have dem-
onstrated that mTOR is activated in gastric cancer about
60% and mTOR activation is strongly correlated with poor
prognosis [10].
A few recent phase III trials and meta-analysis have
demonstrated that survival with capecitabine-based regi-
mens compares favorably with that of 5-ﬂuorouracil-based
regimens as ﬁrst-line therapy for patients with advanced
gastric cancer [11–13]. Bu et al. suggested that the inhib-
itors of mTOR plus 5-FU may have potential anticancer
activity and that downregulation of AP-1 and NF-kappa B
transcription activity might result in a senescence-like
growth arrest [14]. On the basis of these data, we
hypothesized that co-administration of an mTOR inhibitor
with capecitabine enhances anticancer effects in patients
with advanced gastric cancer. In this study, we conducted a
phase I study of capecitabine plus everolimus to determine
the maximum-tolerated dose (MTD) and the dose-limiting
toxicity (DLT) in refractory metastatic gastric cancer
patients.
Patients and methods
A prospective, single center, open-label study with dose
escalation was conducted to evaluate the efﬁcacy and
safety of capecitabine plus everolimus in patients with
metastatic gastric cancer who have failed previous
chemotherapy.
Patient eligibility
Eligibility criteria for study entry were as follows: (1) his-
tologicallyorcytologicallyconﬁrmedadvancedunresectable
or metastatic or recurred gastric adenocarcinoma, (2) age
greater than 18 years, (3) at least one measurable lesion
according to the RECIST (response evaluation criteria in
solid tumors) 1.0 criteria, (4) ECOG (Eastern Cooperative
Oncology Group) performance status 0–2, (5) no evidence of
progression and normal neurologic function within 8 weeks
in patients with metastatic tumors of central nervous system,
(6) patients who failed at least two cytotoxic chemotherapy
regimens (adjuvant chemotherapy administered within
1 year from the study entry date was counted as one regi-
men), (7) adequate organ function; hematologic parameters
(hemoglobin C9.0 g/dl, absolute neutrophil count (ANC)
C1,500/mm
3,p l a t e l e tc o u n t C100,000/mm
3), renal func-
tion (serum creatinine\1.5 mg/dl), and hepatic function
(aspartate aminotransferase, alanine aminotransferase
\2.5 9 upper limits of normal, total bilirubin\3 9 upper
limitofnormal)andserumcalcium[9 mg/dl.Theexclusion
criteria were as follows: (1) patients treated with major
surgery or radiotherapy within 4 week before clinical trial,
(2) patients having hypersensitivity to everolimus or cape-
citabine, (3) patients having diabetes mellitus treated with
oral hypoglycemic agents or insulin injection, (4) patients
with conﬁrmed leptomeningeal carcinomatosis (cytologi-
cally conﬁrmed or neurologic symptoms with evidence of
CT or MRI), (5) grade 2 or more cardiac dysfunction based
on National Cancer Institute Common Terminology Criteria
for Adverse Events (NCI CTCAE, version 3.0), (6) life
expectancy less than 3 months, (7) active gastrointestinal
bleeding which needed transfusion, (8) severe comorbidi-
ties such as active infection and severe cardiopulmonary
dysfunction, (9) patients requiring long-term immunother-
apy such as corticosteroid or other immunosuppressants,
(10) previous or concurrent other malignancies except
treated basal cell or squamous carcinoma of skin or treated
cancer from which the patient had been continuously dis-
ease-free for more than 3 years. Women could not be
pregnant or could not breast-feed and women of child-
bearing potential and sexually active men were strongly
advised to use an accepted and effective method of con-
traception. All patients provided written informed consent.
The protocol and the informed consent form were approved
by the Institutional Review Board.
Administration and dose escalation
Three patients were accrued to each dose level. If none of
the three patients experienced DLT, the dose was increased
in a subsequent group of three patients. If DLT occurred in
1 of the 3 initial patients at a particular dose level, then 3
additional patients were treated at the same dose level for a
total of six patients. If DLT developed in 2 of six patients,
then enrollment was stopped at this dose level, which was
deﬁned as the MTD. The preceding dose level (one level
lower) was designated as the recommended dose (RD) for
the phase II study. If two of the ﬁrst three patients expe-
rienced DLT, then dose escalation was planned to be
stopped and de-escalated to intermediate dose (Level 1A).
Dose escalation scheme is outlined in Table 1. Four
dose levels were planned as follows: Level 1, 5 mg bid/day
of everolimus (D1-D21) and 500 mg/m
2 bid/day of cape-
citabine (D1-14); Level 2, 5 mg bid/day of everolimus
(D1-D21) and 750 mg/m
2 bid/day of capecitabine (D1-14);
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123Level 3, 5 mg bid/day of everolimus (D1-D21) and
1,000 mg/m
2 bid/day of capecitabine (D1-14); and Level 4,
10 mg bid/day of everolimus (D1-D21) and 1,000 mg/m
2
bid/day of capecitabine (D1-14). Treatment was repeated
every 3 weeks until disease progression, patient refusal, or
any serious adverse event. If Level 1 is well tolerated (no
DLT) and level 2 is too toxic (C2 patients suffer DLT in a
cohort of 6 patients), then Level 1A will be tested. (Level
1A: everolimus 5 mg bid, capecitabine 650 mg/m
2 bid).
Treatment was administered when ANC C1,500 mm
3,
platelets C75,000 mm
3, and non-hematologic toxicities
resolved to grade\2. Dose modiﬁcation was primarily for
grade 3–4 toxicities or for grade 2 toxicities deemed
intolerable due to persistence or disease progression. For
toxicities potentially attributable to either drug, the dose of
both drugs was reduced by 25% in capecitabine and 50% in
everolimus per toxicity occurrence; when toxicity could be
attributed primarily to only one agent, only that drug was
modiﬁed (e.g., hand-foot syndrome attributed to capecita-
bine). Modiﬁcations were based on the most severe
toxicity.
Dose-limiting toxicity
DLT was deﬁned as any of following events observed
during cycle 1 of therapy: any grade 3 non-hematologic
toxicity, grade 4 febrile neutropenia, grade 4 anemia or
thrombocytopenia, grade 2 hemorrhage with grade 3
thrombocytopenia, failure to recover neutrophils (1,500/
mm
3) by day 7. Safety was assessed every week for the ﬁrst
cycle of treatment. Adverse events were evaluated
according to the NCI CTCAE, version 3.0. All adverse
events were evaluated until 21 days after the last dose of
study drug.
Immunohistochemistry
Antibodies used were anti-phospho-Akt immunohis-
tochemistry-speciﬁc rabbit IgG antibody (Ab Catalog No
#3787, Cell Signalings, USA) (1:100).
Response evaluation
Pretreatment evaluations included history taking and
physical examination, assessment of performance status,
complete blood count (CBC), and hepatic and renal func-
tion tests. Serum triglycerides and a full lipid proﬁle were
obtained at baseline. Radiological (chest X-ray, computed
tomography) studies to assess response were performed
after every 2 cycles of therapy until disease progression.
Response deﬁnitions were according to Response Evalua-
tion Criteria in Solid Tumors (RECIST) 1.0 [15]. Pro-
gression-free survival (PFS) was deﬁned as the time from
the date of treatment initiation to the date of the ﬁrst
documentation of disease progression (by radiologically or
clinically) or death. Patients with progression-free status
were censored at the last date verifying survival. Overall
survival (OS) was deﬁned as the time from the date of
starting treatment to the date of death. Surviving patients
were censored at the last conﬁrmation date of survival. The
Kaplan–Meier method was used to estimate the median
values of time-to-event variables, such as overall survival
(OS) and progression-free survival (PFS).
Results
Patient characteristics
Fifteen patients were enrolled in this study between
November 2009 and April 2010 at Samsung Medical
Center. The patient characteristics are shown in Table 2.
Nine patients were men, and the median age was 50 (range,
37–72) years. Eight patients (53.3%) had prior gastrectomy
(curative, n = 4; palliative, n = 4), and four patients who
received curative gastrectomy had received adjuvant con-
current chemoradiotherapy. Six patients had received two
previous cytotoxic chemotherapy regimens, and six
patients had three previous chemotherapy regimens before
the study treatment. Thus, majority of patients were heavily
pretreated.
DLT and MTD
Major adverse events occurring during the ﬁrst cycle at each
dose level are shown in Table 3. Grade 3 infection (Four-
nier’s gangrene) occurred in one of the three patients at dose
Level 1; therefore, additional three patients were enrolled to
conﬁrm tolerability. There were no additional DLTs
observed at dose Level 1 in cohort of six patients. Subse-
quently, dose was escalated to Level 2. At Level 2, grade 3
hyperglycemia and grade 3 hyponatremia concurrently
developed in one patient. Three additional patients were
enrolled. Grade 3 mucositis, grade 3 thrombocytopenia,
Table 1 Dose escalation scheme
Dose level RAD001
(mg, q12 h, daily)
Capecitabine (mg/m
2,
q12 h, days 1–14)
Level -1 2.5 500
Level 1 5 500
Level 1A 5 650
Level 2 5 750
Level 3 5 1,000
Level 4 10 1,000
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123grade 3 hyperglycemia/hyponatremia (concomitantly in one
patient), and grade 3 hypophosphatemia occurred as DLTs.
As a consequence, dose Level 2 was considered intolerable,
and doses were de-escalated to the preplanned dose Level
1A (everolimus 5 mg bid, capecitabine 650 mg/m
2 bid).
There was no DLT in the 3 patient cohort at dose Level 1A.
Based on the results, we concluded that the MTD of this
combination regimen was dose Level 2. Grade 3/4 adverse
events in all cycles are shown in Table 4. Most common
severe toxicity was grade 3 mucositis (n = 5). Grade 4
toxicities did not occur in all cycles. There was no grade 3
hand-foot syndrome or diarrhea. Incidence of radiologic
interstitial pneumonia was not documented. There were no
treatment-related mortalities observed in this trial.
Efﬁcacy
A total of 43?? cycles of chemotherapy were adminis-
tered with median of 2 cycles (range 1–10?). All patients
who received at least 1 dose of study treatment were
considered evaluable for toxicity and response. Objective
tumor responses at each dose level are provided in Table 5.
Although there were six patients with stable disease
resulting in disease control rate of 40.0% (95% CI,
16.6–67.7%), none achieved complete or partial response.
After a median follow-up duration of 5.6 months (range,
2.3–8.1 months), median PFS was 1.8 months (95% CI,
0.8–2.8 months) (Fig. 1). The maximum best change
observed was a 28.7% decrease in sum of longest diameters
when compared with baseline (Fig. 2). Of note, remaining
three patients who did not develop DLTs in dose Level 2
continue to receive capecitabine and everolimus and
maintained stable disease.
Immunohistochemistry analysis
Of the 13 cases evaluated, 15.4% (2 of 13) were positive
for phosphor-Akt (Fig. 3). All two patients with phosphor-
Akt (?) had stable disease for 2.8 and 5.6 months,
respectively, after capecitabine and everolimus combina-
tion treatment. Due to the limited number of patients, there
was no signiﬁcant correlation between clinical response
and phosphor-Akt status in this series (P = 0.143).
Discussion
We demonstrated that combination treatment of capecita-
bine and everolimus has tolerable safety proﬁle in meta-
static gastric cancer patients. Based on our results,
everolimus 5 mg twice daily continuously can be safely
added to capecitabine 650 mg/m
2 twice daily D1-14 every
3 weeks in gastric cancer. DLTs observed in this trial were
grade 3 infection (Fournier’s gangrene), grade 3 mucositis,
grade 3 thrombocytopenia, grade 3 hypophosphatemia,
and grade 3 hyperglycemia/hyponatremia (concomitantly in
one patient). The combination of capecitabine and everol-
imus was conveniently administered in an outpatient setting
and very well tolerated. The most commonly observed
grade 3 or greater toxicity was mucositis (33.3% of all
patients) which is concordant with previous study [16–18].
Furthermore, signiﬁcant hematological toxicities requiring
active interventions were not commonly observed as pre-
viously reported [16–18]. Frequently occurring adverse
events related to everolimus were stomatitis/oral mucositis,
fatigue, anorexia, hyperglycemia, hyperlipidemia, elevated
liver enzymes, diarrhea, and hypophosphatemia [19–23]. In
our study, hematologic abnormalities were uncommon with
only four patients with grade 1–3 thrombocytopenia. There
were no cases of neutropenia. Most toxicities were tolerable
grade 1–2 and readily manageable. There was no treatment-
related mortality.
This combination regimen showed promising clinical
activity. Although there were no patients with complete or
Table 2 Patient characteristics (N = 15)
Characteristics No. of patients (%)
Sex
Male 9 (60.0)
Female 6 (40.0)
Age
Median age, years (range) 50 (37–72)
ECOG performance status
0 1 (6.7)
1 13 (86.6)
2 1 (6.7)
No. of prior chemotherapy
Palliative
1 1 (6.7)
2 6 (40.0)
3 6 (40.0)
C4 2 (13.3)
Site of metastasis
Liver 7 (46.7)
Lung 4 (26.7)
Peritoneum 5 (33.3)
Intraabdominal lymph node 9 (60.0)
Ovary/others 4 (26.7)/3 (20.0)
No. of metastasis sites
1 3 (20.0)
2 7 (46.6)
3 4 (26.7)
4 1 (6.7)
ECOG Eastern Cooperative Oncology Group
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123partial response, 6 patients (40%, 95 CI, 16.6–67.7%)
demonstrated stable disease. All of the patients included in
this clinical study were heavily pretreated with cytotoxic
chemotherapy: six patients had received 3 chemotherapy
regimens prior to study treatment and two patients had 4 or
more regimens before study treatment. Nearly half of the
patients (n = 7) had liver metastasis, and one-third (n = 5)
of patients had peritoneal seeding at the time of study
entry. Moreover, one-third of the patients had more than 2
metastatic sites. Importantly, all patients were previously
exposed to 5-FU compound-containing regimens including
capecitabine/cisplatin, 5-FU/cisplatin, or TS-1/cisplatin.
Given the fact that only 50% of metastatic gastric cancer
patients are able to proceed to second-line chemotherapy
[6, 24], and disease control rate of 40% is a promising
activity for salvage chemotherapy. At the time of this
writing, two patients are still receiving capecitabine/
everolimus. The median duration of tumor response in
patients with stable disease was 1.6 months (95% CI,
1.1–2.1 months). One patient has achieved stable disease
for 6 months. Although the follow-up duration is short,
median survival time calculated from the time of study
treatment was 4.6 months (95% CI, 3.9–5.2 months)
(Fig. 4).
Table 3 Adverse events during the ﬁrst cycle
Dose Level 1 (n = 6) Dose Level 2 (n = 6) Dose Level 1A (n = 3)
Grade Grade Grade
1 23 4 12341234
Hematological
Anemia
Thrombocytopenia 1 1 1
Neutropenia
Leukopenia
Non-hematological
Anorexia 3 1
Insomnia 1 1
Dyspepsia 1 1
Nausea 2
Vomiting
Constipation
Fatigue
Diarrhea
Mucositis 1 2 1 2
Rash 1
Pruritus 1 1 1
Sensory neuropathy
Hand-foot syndrome
Febrile neutropenia
Headache 1 1
AST/ALT /1
Hyperbilirubinemia
Hypercholesterolemia
Hypertriglyceridemia 1
Hyperglycemia 1
Hyponatremia 1
Hypokalemia 1
Hypophosphatemia 1 1
Hypocalcemia 1
Proteinuria 1 1
Infection 1**
** Fournier’s gangrene
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123Recent phase II study has demonstrated a promising
antitumor activity of everolimus monotherapy in metastatic
gastric cancer with disease control rate of 56.0% (95% CI,
41.3–70.0%) and median PFS of 2.7 months (95% CI,
6.5–12.1 months) [7]. In this Japanese phase II study, only
8% had peritoneal seeding and 50% of patients had only
Table 4 Adverse events in all cycles
Dose Level 1 (n = 6) Dose Level 2 (n = 6) Dose Level 1A (n = 3)
Grade Grade Grade
1 2 3412 3 41 2 3 4
Hematological
Anemia
Thrombocytopenia 1 2 1
Neutropenia
Leukopenia
Non-hematological
Anorexia 3 2 2
Insomnia 1 1
Dyspepsia 1 1 1
Nausea 1 2
Vomiting 1 1
Constipation
Fatigue 1
Diarrhea
Mucositis 1 3 1 1 3 1 1
Rash 1
Pruritus 1 1 1
Sensory neuropathy
Hand-foot syndrome 2
Febrile neutropenia
Headache 1 1 2
AST/ALT 1/ /1 /1 1/
Hyperbilirubinemia 1
Hypercholesterolemia
Hypertriglyceridemia 1
Hyperglycemia 1
Hyponatremia 1
Hypokalemia 1 1
Hypophosphatemia 1 1 2 1
Hypocalcemia 1
Proteinuria 2 1
Infection 1
Table 5 Response rate
‘‘?’’ or ‘‘??’’ means ongoing
of treatment
Dose level Number of
patients
Total number
of cycles
Overall response
CR PR SD PD
161 1 0 0 1 5
262 3 ? 0033
1A 3 9? 0021
Total 15 43?? 0069
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123one previous chemotherapy regimen before everolimus
monotherapy. In previous pharmacokinetic study, it has
been demonstrated that gastrectomy does not inﬂuence the
rate of oral absorption of everolimus [7]. Currently, a
randomized phase III trial (GRANITE-1) is accruing
patients to compare placebo with everolimus 10 mg once
daily monotherapy in metastatic gastric cancer patients as
second- or third-line treatment. Hence, more efﬁcacy data
of everolimus in gastric cancer will become available soon.
This trial represents the ﬁrst to investigate the safety of a
cytotoxic agent with continuous daily dosing schedule of
everolimus. Given the convenient administration of two
oral drugs and excellent tolerability, capecitabine and
everolimus may be a novel therapeutic option for meta-
static gastric cancer patients who have failed the standard
5-FU-based chemotherapy. The recommended dose for
subsequent phase II trial is capecitabine 650 mg/m
2 twice
daily D1-14 and everolimus 5 mg twice daily continuously.
We are currently conducting a phase II trial in this clinical
setting to investigate the efﬁcacy and toxicity proﬁle of the
regimen along with correlative biomarker study. The phase
II clinical trial is anticipated to be completed by 2011.
Conﬂict of interest None.
median PFS:1.8 months, 95% CI, 0.8 – 2.8 months 
Fig. 1 Kaplan–Meier curve of progression-free survival
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Fig. 2 Maximum best change in tumor size from baseline. Decrease
in best percent change from baseline = 28.7%, increase in best
percent change or no percent change from baseline = 57.7%. Blue
bar stable disease. Yellow bar progressive disease
Fig. 3 Positive immunohistochemical staining for phosphor-AKT in
the gastric adenocarcinoma tissue specimen (9400)
median OS: 4.6 months, 95% CI, 3.9 – 5.2 months 
Fig. 4 Kaplan–Meier curve of overall survival
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